Metraipolis › archive › dc_c08b0ba99d2d

Out"FOX"ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy — Europe PMC PMID:42454125

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42454125
DOI
10.3389/fmed.2026.1883380
License (as archived)
solo-consultazione
Archived
2026-10-18T14:21:15.314Z
SHA-256 of the archived text
fc5bff0f339e2e1b44e0475355b71b4b5cba1b6bf2e3f9744a384811f8c0fe41
Stable URL of this page
https://metraipolis.com/documento/dc_c08b0ba99d2d

How to cite

Out"FOX"ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy — Europe PMC PMID:42454125 — Europe PMC (en), https://europepmc.org/article/MED/42454125 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c08b0ba99d2d (Metraipolis archive dc_c08b0ba99d2d, sha256 fc5bff0f339e2e1b44e0475355b71b4b5cba1b6bf2e3f9744a384811f8c0fe41)
BibTeX
@misc{dcc08b0ba99d2d,
  title = {Out"FOX"ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy — Europe PMC PMID:42454125},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42454125},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c08b0ba99d2d; sha256 fc5bff0f339e2e1b44e0475355b71b4b5cba1b6bf2e3f9744a384811f8c0fe41},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42454125. Agents can read the archived copy with the MCP tool read_document.